Frank Ruffo - 01 Mar 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Financial Officer
Signature: /s/ Mark Ballantyne, Attorney-in-fact
Issuer symbol: ACRS
Transactions as of: 01 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2022, 17:08:11 UTC
Previous filing: 11 Feb 2022
Next filing: 14 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+25,750	+15%		198,109	01 Mar 2022	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+8,300	+4.2%		206,409	01 Mar 2022	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+8,297	+4%		214,706	02 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+155,200		$0.000000	155,200	01 Mar 2022	Common Stock	155,200	$14.94	Direct	F2
transaction	ACRS	Restricted stock units	Award	$0	+44,300		$0.000000	44,300	01 Mar 2022	Common Stock	44,300		Direct	F1, F3
transaction	ACRS	Restricted stock units	Options Exercise	$0	-25,750	-50%	$0.000000	25,750	01 Mar 2022	Common Stock	25,750		Direct	F1, F4
transaction	ACRS	Restricted stock units	Options Exercise	$0	-8,300	-25%	$0.000000	24,900	01 Mar 2022	Common Stock	8,300		Direct	F1, F5
transaction	ACRS	Restricted stock units	Options Exercise	$0	-8,297	-33%	$0.000000	16,595	02 Mar 2022	Common Stock	8,297		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
F3	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
F4	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F5	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F6	The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.